BRD4 and Miyoshi myopathy: However, the MM cell lines tested here were not affected by the JAK2 inhibitor ruxolitinib, indicating the primary mechanism of action of SG3 and MA9 in compromising MM cell survival via inhibition of ULK1/3 or BRD4.